Medac Pharma
Medac Pharma is the UK subsidiary of privately-held German pharmaceutical company medac GmbH, distributing generics, biosimilars, cell therapies and diagnostics across 91 countries with focus on rheumatology, urology, haematology and oncology, and operating a CDMO business.
- Company typePrivate
- Founded1970
- HeadquartersStirling, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medac Pharma does
medac Pharma is the UK operating subsidiary of medac GmbH, a privately-held German pharmaceutical company founded in 1970 in Wedel near Hamburg. The group employs over 2,000 people worldwide and distributes a portfolio of generics, biosimilars, original products, diagnostics and cell therapies across 91 countries, with primary therapeutic focus on rheumatology, urology, haematology and oncology. Manufacturing is vertically integrated through ONCOTEC Pharma Produktion GmbH in Dessau-Roßlau (cytostatics) and oncomed manufacturing a.s. in Brno (production and logistics), with UK operations based at Scion House, Stirling University Innovation Park. The company also operates a CDMO business providing aseptic processing of injectables, sterile manufacturing and technology transfer to pharmaceutical and biotech partners under FDA, ANVISA and PMDA compliant frameworks.
Core proprietary technology assets include the closed instillation system pioneered in 1988 for non-muscle invasive bladder cancer treatment, now regarded as a global gold standard, and proprietary conditioning therapy for allogeneic stem cell transplantation that expanded treatment eligibility to elderly, co-morbid and pediatric patients. medac is a recognised leading supplier of subcutaneous methotrexate for autoimmune diseases and produces chemotherapy agents (Doxorubicin, Epirubicin, Dacarbazine, Carmustine), BCG-medac for bladder cancer, and a growing biosimilar portfolio. FY 2023/24 output reached 48 million units assembled and packaged, including 9 million pens and 10 million syringes, with a 98% average delivery capability since 2021.
The business model is primarily product-driven: pharmaceutical sales to healthcare institutions and professionals (oncologists, urologists, rheumatologists, haematologists) routed through wholly-owned subsidiaries and branch offices across Europe, Japan and the UAE. A secondary revenue stream consists of contract development and manufacturing services for external pharma and biotech partners requiring aseptic injectable fill-finish. Pricing is not publicly disclosed, consistent with prescription-based institutional sales channels, and the company pursues a value-oriented, long-term management strategy emphasising reliable supply and unmet therapeutic need rather than direct-to-consumer marketing.
Medac Pharma firmographics
Firmographics- Name
- Medac Pharma
- Legal name
- medac Pharma LLP
- Website
- https://medacpharma.co.uk
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medac Pharma is the UK subsidiary of privately-held German pharmaceutical company medac GmbH, distributing generics, biosimilars, cell therapies and diagnostics across 91 countries with focus on rheumatology, urology, haematology and oncology, and operating a CDMO business.
- Ownership category
- akta.pro rank
Medac Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industries
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where Medac Pharma is headquartered
LocationHeadquarters
- HQ city
- Stirling
- HQ country
- United Kingdom
- HQ region
- Europe
Offices16 records
Markets served
Medac Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Sales: Sales of proprietary pharmaceutical products including generics, original products, and biosimilars in the therapeutic areas of rheumatology, urology, haematology, and oncology. Products are distributed to 91 countries worldwide.
- CDMO Services: Contract Development and Manufacturing Organization services offering aseptic processing of injectables, sterile manufacturing, and technology transfer for clinical and commercial sectors globally. Partners include start-ups, biotech and pharmaceutical companies.
- Diagnostics: Development and distribution of diagnostics products alongside pharmaceutical products.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Medac Pharma product offering
Product offeringCore offering
Medac Pharma develops, manufactures, and distributes proprietary pharmaceutical products — including generics, biosimilars, cell therapies, and original products — across four therapeutic areas: rheumatology, urology, haematology, and oncology. The company supplies prescription products to healthcare professionals and institutions in 91 countries, and operates CDMO services offering aseptic injectable manufacturing and technology transfer to pharmaceutical and biotech partners. Manufacturing is conducted in Germany and the Czech Republic under European quality standards.
Product overview
Medac Pharma is a pharmaceutical company with a diverse portfolio spanning four therapeutic focus areas: rheumatology, urology, oncology, and haematology. The company offers original products, generics, and biosimilars as well as diagnostics. Key products include BCG-medac for bladder cancer treatment, methotrexate for autoimmune diseases, and cell therapy products for stem cell transplantation. Medac also operates as a CDMO (Contract Development and Manufacturing Organization) providing sterile injectable manufacturing services. The product portfolio includes chemotherapy agents (Doxorubicin, Epirubicin, Dacarbazine, Carmustine), immunotherapies (BCG-medac), and biosimilars, with manufacturing capabilities through subsidiaries oncotec GmbH and oncomed a.s.
Differentiator
Problem solved
Functional benefit
Brands
- BCG-medac: Contains Bacillus Calmette Guérin, available as powder and solvent for intravesical suspension, used for bladder cancer treatment.
- Carmustine medac
- Dacarbazine
- Doxorubicin
- Epirubicin
Products and services
- BCG-medac Pharmaceutical product containing Bacillus Calmette Guérin available as powder and solvent for intravesical suspension, used for the treatment of non-muscle invasive bladder cancer (NMIBC) via medac's proprietary closed instillation system.
- Carmustine medac Powder and solvent for concentrate for solution for infusion used in haematology, with marketing authorisation transferred from Obvius to medac.
- Dacarbazine Powder for solution for injection or infusion used in oncology treatments.
- Doxorubicin Solution for infusion used in oncology treatments.
- Epirubicin Solution for injection used in oncology treatments.
- Methotrexate Crucial drug in the treatment of autoimmune diseases including rheumatic diseases, with medac recognised as a leading supplier of subcutaneous methotrexate and continuous improvement of delivery systems.
- Cell Therapy Products Products for cell therapy, particularly used in conditioning therapy prior to allogeneic stem cell transplantation for haematological diseases in children and adults, providing access for patient groups previously ineligible including elderly and co-morbid patients.
- Biosimilars Biosimilar products for the treatment of autoimmune diseases, forming part of medac's strategic expansion of their biosimilar niche portfolio.
- CDMO Services Contract Development and Manufacturing Organization services offering aseptic processing of injectables, sterile manufacture of medicinal products, formulation and filling of sterile injectables for clinical and commercial sectors. Services include technology transfer, regulatory compliance support (FDA, ANVISA, PMDA), and a modular cooperation model for pharmaceutical, biotech, and start-up partners.
Quantifiable outcome
- 98% delivery capability maintained (average since 2021)
- +3 more outcomes
Companies that use Medac Pharma
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles2 records
Medac Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Medac Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Start-ups, Biotech and Pharmaceutical Companiescoremedac offers a modular cooperation model for pharmaceutical partnerships ranging from full product development to final approval steps. Services include strategic planning, targeted due diligence, gap analyses, comprehensive product development plans, and access to an established network of key opinion leaders, academics, non-profit organisations, experts and patient representatives.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Medac Pharma competitors and assessment
Company assessmentDirect peers
- Stada Arzneimittel: German-based private specialty pharma offering generics, biosimilars, and consumer health products across Europe with a comparable CDMO-style manufacturing footprint. Closest match in size, geography, and product mix to medac.
- Hikma Pharmaceuticals: UK-listed specialty pharma focused on generic injectables, biosimilars, and branded products, with strong manufacturing capabilities and CDMO services — highly comparable to medac's injectable and biosimilar portfolio.
- Aspen Pharmacare: South African specialty pharma with global generics, biosimilars, and sterile injectable manufacturing operations, serving oncology and autoimmune indications. Comparable therapeutic-area focus and CDMO exposure.
- Aurobindo Pharma: India-based generics and injectables manufacturer with growing CDMO business and biosimilar pipeline. Comparable product mix in cytostatics and sterile injectables, though at significantly larger scale.
- Siegfried Holding: Swiss CDMO with both API and drug product manufacturing for small-molecule generics and innovative pharma partners. Comparable CDMO service model and European manufacturing footprint.
- Dr. Reddy's Laboratories: India-based generics manufacturer with growing biosimilar and CDMO business, including sterile injectables and oncology products. Comparable product mix and growing European footprint.
Broad incumbents
- Viatris: Global generics and biosimilars major formed from Mylan and Upjohn, with broad portfolio across therapeutic areas including oncology and autoimmune. Significantly larger than medac but competes in the same generic injectable and biosimilar segments.
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with significant biosimilar pipeline and injectable capabilities. Competes with medac across multiple therapeutic areas and geographies.
- Catalent: Major global CDMO offering sterile injectable fill-finish, biologics, and oral dose manufacturing. Directly comparable CDMO service portfolio though at significantly larger scale.
Regional players
- Almirall: Spanish specialty pharma focused on dermatology and specialty therapeutic areas with European commercial footprint. Comparable mid-cap European specialty pharma profile though different therapeutic focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks8 records
Key highlights6 records
Customer concentration
Medac Pharma social profiles
Digital presenceMedac Pharma compliance and trust
Trust signalCompliance5 records
Medac Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medac Pharma leadership team
Management profileNumber of profiles
Profiles4 records
Medac Pharma subsidiaries and ownership
Company hierarchySubsidiaries7 records
Medac Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medac Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medac Pharma
What does Medac Pharma do?
Medac Pharma develops, manufactures, and distributes proprietary pharmaceutical products — including generics, biosimilars, cell therapies, and original products — across four therapeutic areas: rheumatology, urology, haematology, and oncology. The company supplies prescription products to healthcare professionals and institutions in 91 countries, and operates CDMO services offering aseptic injectable manufacturing and technology transfer to pharmaceutical and biotech partners. Manufacturing is conducted in Germany and the Czech Republic under European quality standards.
Is Medac Pharma a public or private company?
Medac Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Medac Pharma founded?
Medac Pharma was founded in 1970. It employs 11 to 50 people.
Where is Medac Pharma based?
Medac Pharma is headquartered in Stirling, United Kingdom, in the Europe region.
How does Medac Pharma make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO Services and diagnostics.
Who are Medac Pharma's main competitors?
Direct peers on record are Stada Arzneimittel, Hikma Pharmaceuticals, Aspen Pharmacare, Aurobindo Pharma, Siegfried Holding and Dr. Reddy's Laboratories. Broad incumbents are Viatris, Teva Pharmaceutical Industries and Catalent. Almirall is listed as a regional player.
Does Medac Pharma have an API?
No public API is recorded for Medac Pharma.
What industry is Medac Pharma in?
Medac Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.